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Abstract
Background: Recepteur d'origine nantais (RON) is a receptor tyrosine kinase that is activated by a
serum-derived, macrophage stimulating protein (MSP) growth factor and is expressed in many malignant
tumors. The aim of the present study was to reveal the protein expression profile of RON and its
relationship with clinicopathological characteristics of gastric carcinoma and prognosis.
Methods: Gastric carcinoma tissue from 98 patients, along with 29 specimens of paraneoplastic tissue and
10 specimens of normal gastric mucosa, were examined by immunohistochemistry (IHC). Western blot
analysis of 19 samples of gastric carcinoma tissue and corresponding paraneoplastic tissue, 8 specimens of
normal gastric mucosa, and 2 specimens of normal lymph node samples also detected expression of a
splice variant of RON, RONΔ165. All samples obtained were accompanied by patient follow-up data that
ranged from 3 to 89 months (median time: 22 months).
Results: The rate of positive RON expression differed significantly between gastric carcinoma tissues
[56.1%, (55/98)] and paraneoplastic tissues [25.6%, (8/29)] (p = 0.007). In contrast, RON expression was
absent in normal gastric mucosa samples. RON expression positively correlated with the invasive depth
of the tumor (p = 0.019), perigastric lymph nodes metastasis (p = 0.019), and TNM stage (p = 0.001).
However, RON expression was independent of tumor growth pattern according to Bormann criteria (p
= 0.209), histopathological grade (p = 0.196), and incidence of distant metastasis (p = 0.400). RON
expression was not related to a patient's survival rate (p = 0.195). RONΔ165 was strongly expressed in
fresh gastric carcinoma tissue, corresponding paraneoplastic tissue, and perigastric lymph nodes with
metastatic carcinoma. In contrast, expression of RONΔ165 was not observed in normal gastric mucosa
and normal lymph node tissue samples.
Conclusion: RON expression is significant in gastric carcinoma tissue and corresponding paraneoplastic
tissue, but is not expressed in normal gastric mucosa. Expression of RONΔ165 was similarly observed in
gastric carcinoma tissue and in metastases present in lymph node tissues. We hypothesize that RON and
its splice variant play an important role in the occurrence, progression, and metastasis of gastric carcinoma,
and therefore may represent a useful marker to evaluate the biological activity of gastric carcinoma.
Published: 28 November 2008
BMC Cancer 2008, 8:353 doi:10.1186/1471-2407-8-353
Received: 18 June 2008
Accepted: 28 November 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/353
© 2008 Dong-hui et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:353 http://www.biomedcentral.com/1471-2407/8/353
Page 2 of 7
(page number not for citation purposes)
Background
Morbidity from gastric carcinoma is increasing each year,
while the age of onset is decreasing. In China, gastric car-
cinoma is the top malignant tumor in both categories of
morbidity and mortality [1]. Recepteur d'origine nantais
(RON) is a receptor tyrosine kinase (RTK) that belongs to
the MET proto-oncogene family. Recent studies of a RON
knockout mouse model shows that complete disruption
of the RON gene is embryonic lethal [2], demonstrating
that RON is essential in embryonic development. RON is
activated by a serum-derived, macrophage stimulating
protein (MSP) growth factor, and studies have shown that
RON is expressed in many malignant tumors and plays a
role in their occurrence and progression.
Zhou et al. [3] found that RON is strongly expressed in
colorectal carcinomas, and they identified three splicing
variants of RON (RONΔ160, RONΔ165, and RONΔ155).
The expression of RON and its variants was associated
with the progression of colorectal carcinoma. Other stud-
ies have shown that the expression of RON and its splice
variants can precipitate colon epithelial cell colony forma-
tion and increase their viability. When expression of RON
and its splice variants were targeted by siRNA in rectal
tumor cell strains, proliferation and metatasis were signif-
icantly inhibited, concomitant with increased apoptosis.
Based on these data, RON and its splice variants are
hypothesized to have an important role in the occurrence,
progression, and metastasis of rectal cancer [4]. Similarly,
studies of RON expression in both breast and bladder can-
cer tissues has shown increased levels of RON expression
and a correlation with histological grade [5,6].
To our knowledge, the role of RON in gastric cancer has
only been studied by Collesi et al [7]. In this study the
splice variant of RON, RONΔ165, was detected in the gas-
tric carcinoma cell strain, KATO-III. RONΔ165 was shown
to enhance the invasion of gastric cancer cells, indicating
a role for the splice variant of RON in the malignant trans-
formation of gastric cells to a carcinoma. In this study, we
examine the expression of RON in the gastric carcinoma
tissue of 98 patients using the Envision immunohisto-
chemistry (IHC) method. To examine expression of
RONΔ165, Western blotting of fresh gastric carcinoma tis-
sue was performed. The patients enrolled in our study
were monitored between 3 and 89 months post-operation
to investigate the association of RON expression, includ-
ing its splice variant, to the clinicopathological character-
istics of gastric carcinoma and prognosis. Due to the
complex pathogenesis of gastric carcinoma, therapeutic
efficacy has not proven to be very effective. Thus, it is
important to investigate the pathogenesis of gastric carci-
noma to find new therapeutic targets.
Methods
Patient samples
Paraffin embedded tissue samples from 98 patients who
underwent surgery for pathologically confirmed gastric
carcinoma in the First Affiliated Hospital of College of
Medicine of Zhejiang University between 1998 and 2003
were obtained. Gastric samples were used with the con-
sent of the patients and permission of the Ethics Commit-
tees of Hospitals. Seventy men and 28 women, ranging in
age from 21 to 76 years (median age 58 years), were
included in this study. Patient diagnosis included 78 cases
of sinus ventriculi carcinoma, 16 cases of gastric cardia
carcinoma, and 4 cases of total gastric carcinoma. Post-
surgery pathological reports diagnosed 2 well-differenti-
ated adenocarcinomas, 21 moderately differentiated ade-
nocarcinomas, 69 poorly differentiated adenocarcinomas,
1 signet-ring cell carcinoma, 2 mucinous adenocarcino-
mas, and 3 severe dysplasia with cancerization. According
to UICCTNM (1998), the histological grade of the sam-
ples was determined to include 26 stage I cases, 14 stage II
cases, 30 stage III cases, and 28 stage IV cases. The follow-
up rate for our patients was 92%, with 8 patients not avail-
able to complete the follow-up. The follow-up period was
between 3 and 89 months (median time of 22 months)
following surgery. Ten samples of normal gastric mucosa
were examined as controls. Nineteen samples of fresh gas-
tric carcinoma tissue, paraneoplastic tissue, and positive
perigastric lymph node tissue were collected for Western
blot analysis. Ten samples of normal gastric mucosa were
also included as controls.
Immunohistochemistry
Paraffin samples were sectioned into 4 μm thick slices
which were deparaffinized, hydrated and incubated for 20
min in 0.3% H2O2  to inhibit endogenous peroxidase
activity. For antigen retrieval, samples were incubated
with 0.1 M citrate buffer (pH 6.0) and heated in a pressure
cooker for 8 min. After rinsing in TBS, the slides were incu-
bated with 3% normal donkey serum (NDS) in TBS for 20
min to prevent non-specific binding of the first antibody.
Anti-RON rabbit monoclonal antibody Ron β (C-20)
(Santa Cruz Biotechnologies, USA) was used at 1:400. The
Envision kit (DAKO) was used according to the manufac-
turer's directions, and bound antibody was detected using
DAB. Samples were also co-stained with hematoxylin.
Samples were observed under a light microscope and a
PBS-only staining sample was used as a background con-
trol.
Evaluation criteria for RON detection by 
immunohistochemistry
The assessment of the grade of staining was determined
using a blinded evaluation procedure by experienced
pathologists. High-power fields (400×) using standard
light microscopy were divided into ten sections whichBMC Cancer 2008, 8:353 http://www.biomedcentral.com/1471-2407/8/353
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were randomly scored. Tumor cells with buffy particles in
the intracytoplasm were scored as positive, and the per-
centage of positive tumor cells and staining intensity for
each sample was recorded. Tumor cells that did not stain
for RON expression were scored as negative, cells that
weakly stained were scored as 1, moderate staining was
scored with a 2, and strongly staining samples were scored
as 3. Of the positive tumor cells detected,< 5% were nega-
tive, between 5 and 24% were scored as 1, 25–49% were
scored with a 2, and > 50% were scored with a 3. The
cumulative score of the tumor cells identified in a sample
determined a sample's final score. Based on the final
score, the tumor tissue was determined to be negative
(score of 0–2), or positive (score of 3–6) for RON expres-
sion.
Protein immunoblotting
Fifty micrograms of total protein for each sample was sep-
arated by electrophoresis on a 10% polyacrylamide gel
and transferred to PVDF membrane (Millipore). Detec-
tion of RON protein was performed using an anti-RON
rabbit monoclonal antibody Ron β (C-20) (Santa Cruz
Biotechnologies, USA) (1:400). Antibody binding was vis-
ualized using an anti-rabbit antibody conjugated to horse-
radish peroxidase and an Enhanced chemiluminescence
kit (ECL) (Biological Industries, Inc. Israel). β-actin was
used as a loading control.
Statistical analysis
SPSS 13.0 statistical software was used to identify the sta-
tistical significance of our data using fourfold tables or the
R × C table χ2 test. Survival curves were evaluated using the
Kaplan-Meier method and comparisons of survival rates
were tested using a Log-rank test.
Results
RON expression in gastric tissue and paraneoplastic tissue
RON protein was observed in the cytolymph, but not in
the nucleolus, of gastric carcinoma cells and typically
appeared as a buffy granulo-staining (Fig. 1). The percent-
age of positive tumor cells and the staining intensity for
each sample was recorded. For the 98 patient samples
evaluated, RON expression was observed in 56.1% of the
gastric carcinoma tissues (55/98), but not in samples of
normal gastric mucosa. In gastric carcinoma paraneoplas-
tic tissue, which was collected from the gastric mucous
layer 0.5 cm away from the gastric carcinoma specimens,
RON protein was observed in 25.6% of samples (8/29).
These data represent a significant statistical difference in
RON protein expression between gastric carcinoma tissue
and its associated paraneoplastic tissue (χ2 = 7.290, p =
0.007).
RON protein expression in relation to the pathology of 
gastric carcinoma
RON protein expression was not found to be associated
with gender, age, or diseased region (p > 0.05). However,
in gastric carcinoma tissues, the deeper a carcinoma cell
infiltrated, the more strongly RON protein was expressed
(p = 0.019). RON protein expression was also found to
positively correlate with perigastric lymph node metasta-
sis and clinical pathology stage with statistical significance
(p = 0.019, p = 0.001) (Table 1). In contrast, there were no
significant statistical differences in RON expression with
the pathology grading, Borrmann type, or presence of
metastasis. However, it was observed that RON expression
was stronger in the Borrmann III/IV group (63.6%) than
in the Borrmann I/II group (53.8%), stronger in the dis-
tant metastasis group (68.2%) than in the non-distant
metastasis group (52.6%), and stronger in the histologi-
cally lower differentiated group (52.4%) than in the mod-
erately and highly differentiated histology group (39.1%).
There were no significant statistical differences for these
comparisons (p = 0.209; p = 0.400; p = 0.196), respec-
tively (Table 1).
RON expression and survival rates
For the 90 patients enrolled in this study that were fol-
lowed post-operationally, no significant statistical differ-
ence in survival rates was found between patients with
RON-positive gastric carcinoma samples versus RON-neg-
ative gastric carcinoma samples (Fig. 2).
Detection of the RONΔ165 splice variant
In the 19 samples of fresh gastric carcinoma tissues col-
lected, along with corresponding paraneoplastic tissues,
and pathologically confirmed perigastric lymph nodes
with metastatic carcinoma, the splice variant of RON,
RONΔ165, was expressed. In contrast, no expression of
RON protein was observed in normal gastric mucosa or
normal lymph node tissue (Fig. 3, 4).
Discussion
In the current study, we show by both IHC and Western
blot, that RON expression is not detectable in normal gas-
tric mucosa. These observations are consistent with results
from Okino et al [8]. However, staining of RON in carci-
noma tissues and corresponding paraneoplastic tissues by
IHC showed significant expression of RON relative to nor-
mal gastric mucosa samples. Western blot analysis pro-
vided more specific information regarding RON
expression with detection of RONΔ165 in gastric carci-
noma tissues, corresponding paraneoplastic tissues, and
lymph nodes with carcinoma metastases. These data indi-
cate that expression of full-length RON, as well as a vari-
ant of RON, are expressed during the process of malignant
transformation of gastric epithelial cells. Based on these
data and work in other studies on the role of RON in tum-BMC Cancer 2008, 8:353 http://www.biomedcentral.com/1471-2407/8/353
Page 4 of 7
(page number not for citation purposes)
Detection of RON expression by immunhistochemistry Figure 1
Detection of RON expression by immunhistochemistry. A, H) Detection of RON in a poorly differentiated gastric ade-
nocarcinoma sample. 200× and 400 × magnification. B, E) Magnified view of RON detection in a sample of poorly differentiated 
gastric adenocarcinoma. 400× and 200× magnification. C) Detection of RON in a sample of signet-ring cell carcinoma. 400× 
magnification. D) Detection of RON in a sample of moderately differentiated gastric adenocarcinoma. 400× magnification. F) 
Detection of RON in a sample of moderately differentiated gastric adenocarcinoma. 200× magnification. G) Detection of RON 
in a sample of signet-ring cell carcinoma. 400× magnification.BMC Cancer 2008, 8:353 http://www.biomedcentral.com/1471-2407/8/353
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origenic phenotypes, we hypothesize that RON may act as
an oncogene to promote the occurrence, progression,
invasion, and metastasis of gastric cancer.
Previous studies have shown that expression of RON cor-
relates with the invasion of tumor cells. Maggiora et al [9]
reported that RON was expressed in 55% of ovarian can-
cer tissues. Furthermore, if an ovarian cancer cell line that
strongly expresses RON is induced by MSP, tumor growth
and invasion is significantly enhanced. Based on these
data, it was hypothesized that RON plays a role in the pro-
gression of ovarian cancer. Similarly, Chan et al [10]
showed that expression of RON promoted the growth and
malignant transformation of skin papillomas, and Cheng
et al [6] showed that strong expression of RON in bladder
cancer cell lines correlated with increased proliferation
and apoptosis inhibition. The latter study also demon-
Table 1: Relationship of RON expression to pathology parameters
RON RON Χ2 p
(+) (%) (-)
Invasive Depth
Early gastric cancer 5 (29.4) 12
Infiltrated to muscular layer 15 (51.7) 14 7.795 p = 0.019
Infiltrated to serous membrane 35 (67.3) 17
TNM Stage
Stage 14 (35.0) 26 12.245 p = 0.001
Stage 41 (70.7) 17
Metastases to Lymph Nodes
N0 11 (37.9) 18
N1–3 44 (63.8) 25 5.535 p = 0.019
Borrmann Grade
I/II group 14 (53.8) 12
III/IV group 35 (63.6) 20 0.708 p = 0.400
Others 6 11
Histology Grade
Moderately & highly differentiated 9 (39.1) 14 1.577 p = 0.209
Less differentiated * 39 (54.2) 33
Others** 0 3
Distant Metastasis
M0 40 (52.6) 36 1.675 p = 0.196
M1 15 (68.2) 7
*Includes poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous adenocarcinoma; ** Severe dysplasia with cancerization.
Survival curve for RON+ versus RON-patients Figure 2
Survival curve for RON+ versus RON-patients.
Western blot analysis of RON expression in gastric carci- noma tissue, paraneoplastic tissue, and perigastric lymph  nodes Figure 3
Western blot analysis of RON expression in gastric 
carcinoma tissue, paraneoplastic tissue, and perigas-
tric lymph nodes. Duplicate samples of gastric carcinoma 
tissue (T), paraneoplastic tissue (P), and metastatic lymph 
node (L) tissues were analyzed for expression of RONΔ 165 
(165 kDa). Normal gastric mucosa (N) and normal lymph 
node (NL) tissue samples were compared. β-actin (44 kDa) 
was used as a loading control.BMC Cancer 2008, 8:353 http://www.biomedcentral.com/1471-2407/8/353
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strated that the expression of RON in gastric carcinoma
positively correlated with the invasive depth of the gastric
cancer cell and lymph nodes metastasis, and the level of
expression increased significantly with higher clinical
pathologies of gastric cancer. Therefore, strong expression
of RON in gastric cancer tissues may serve as a marker to
indicate a conversion of normal cells to a malignant phe-
notype, which associated with increased tumor cell inva-
sion and metastasis, would be associated with a poor
prognosis for long-term survival. The proximity of gastric
cancer tissue to the epithelial dysplasia of the stomach
results in the susceptibility of the epithelial dysplasia of
the stomach to precancerous lesions. Therefore, by report-
ing the expression of RON in paraneoplastic tissue, which
was collected ~0.5 cm away from the gastric carcinoma
samples, we are providing data to support our hypothesis
that RON plays an important role in promoting gastric
cancer and may serve as a marker for the conversion of tis-
sues to a malignant phenotype.
In previous studies looking at the relationship between
RON expression and survival rates, Lee et al [11] found
that MET and RON were independent prognostic factors
of long-term recurrence of breast cancer, and that speci-
mens positive for MET and RON expression had a signifi-
cantly lower 10-year disease-free survival rate. Similarly,
Cheng et al [6] reported a lower survival rate for bladder
cancers positive for both MET and RON. In contrast, we
found that the survival rate of patients positive for RON
expression was not lower than the survival rate for the
RON-negative patient group. It is possible that the sur-
vival rate of patients with gastric cancer can be affected by
many factors, and our follow-up data was not sufficient to
provide additional insight into which factors might be
important.
Conclusion
The results of this study show that RON is expressed in
gastric cancer, but not in normal gastric mucosa. Further-
more, the expression rate of RON in gastric cancer posi-
tively correlates with the invasive depth, the clinical
pathologic stage, and extent of lymph node metastasis.
We hypothesize that RON plays an important role in the
occurrence, progression, invasion, and metastasis of gas-
tric cancer, and therefore could be an important marker in
assessing the biological behavior of gastric cancer. The
results of our studies provide a foundation from which to
further identify the mechanistic details of the role of RON
in gastric cancer in order to identify RON as a therapeutic
target in gastric cancer.
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